Syngeneic Mouse Models

Syngeneic modeling utilizes immunocompetent mice with original strain tumors to study immunology as a form of cancer therapy. This approach offers cost-effective and easy model validation. Ichor Life Sciences has a wide selection of characterized models along with the ability to perform a variety of other models along with onboarding new models of interest.

Contact Us
In Vivo Disease Models Oncology & Immuno-Oncology Models Syngeneic Mouse Models

PDAC Mouse Model: UNKC06141

The UNKC6141 model is useful in understanding pancreatic ductal adenocarcinoma progression, metastasis and heterogeneity.

B16-F10 Mouse Model

B16-F10 is used in both syngeneic and immunocompromised models and is useful in studying tumor regression in melanoma models.

Lewis Lung Carcinoma Mouse Model: LL/2

The LL/2 mouse model serves in generating applicable syngeneic tumor characterization of immunotherapies that can be beneficial to lung cancer.

Renca Mouse Model

Renca is a mouse renal adenocarcinoma cell line that is used in generating syngeneic models, its characteristics make it a prime model for studies on angiogenesis and immune checkpoint inhibitors such as PD-1.

CT-26 Mouse Model

A colon cancer mouse model derived from BALB/c mice, this model is useful for murine solid tumors and immunogenic tumor models for colorectal cancer.

EMT6 Mouse Model

The EMT6 mouse model can be used as a powerful immuno-oncology tool due to the favorable immune profile and responsiveness to immune checkpoint blockades.

4T1 Mouse Model

4T1 cells most closely mimic triple-negative breast cancer (TNBC) which is responsible for over 17% of breast cancer worldwide per year and thus serve as the ideal model for preclinical TNBC studies.

Tell us about your unique project needs.

Most projects start within 4 weeks.

Contact Us

Frequently Asked Questions

Syngeneic mice have intact immune systems that allow us to study different immuno/cancer therapies by using tumor tissues derived from the same genetic background as the mouse of interest.

Typical studies can be executed within 3-4 weeks of signing a quote. During this time, specific cell lines will be expanded in culture and models prepared. Typical models take 4-6 weeks for completion post initiation.

Yes! The team at Ichor can work with your team to develop new model onboarding. We have a vast selection of syngeneic cell lines available for use and our team of experts will work with you to meet your needs.